MX2020010716A - Metodo para escindir de la fase solida peptidos unidos a una fase solida. - Google Patents

Metodo para escindir de la fase solida peptidos unidos a una fase solida.

Info

Publication number
MX2020010716A
MX2020010716A MX2020010716A MX2020010716A MX2020010716A MX 2020010716 A MX2020010716 A MX 2020010716A MX 2020010716 A MX2020010716 A MX 2020010716A MX 2020010716 A MX2020010716 A MX 2020010716A MX 2020010716 A MX2020010716 A MX 2020010716A
Authority
MX
Mexico
Prior art keywords
solid phase
cleavage
bound peptides
bound
polypeptide
Prior art date
Application number
MX2020010716A
Other languages
English (en)
Inventor
Bernd Henkel
Norbert Pleuss
Manfred Gerken
Wolfgang Fiedler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2020010716A publication Critical patent/MX2020010716A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C07K1/122—Hydrolysis with acids different from HF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

La invención se refiere a un método para la escisión de un polipéptido unido a una fase sólida de la fase sólida, comprendiendo el método poner en contacto la fase sólida a la que está unido el polipéptido con una composición que consiste esencialmente en ácido trifluoroacético y 1,2-etanoditiol, a una temperatura en el intervalo de aproximadamente 23°C a aproximadamente 29°C.
MX2020010716A 2018-04-10 2019-04-10 Metodo para escindir de la fase solida peptidos unidos a una fase solida. MX2020010716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166546 2018-04-10
PCT/EP2019/059083 WO2019197466A1 (en) 2018-04-10 2019-04-10 Method for cleavage of solid phase-bound peptides from the solid phase

Publications (1)

Publication Number Publication Date
MX2020010716A true MX2020010716A (es) 2021-03-09

Family

ID=62063280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010716A MX2020010716A (es) 2018-04-10 2019-04-10 Metodo para escindir de la fase solida peptidos unidos a una fase solida.

Country Status (12)

Country Link
US (1) US11560402B2 (es)
EP (1) EP3774837A1 (es)
JP (1) JP7434169B2 (es)
KR (1) KR20200142033A (es)
CN (1) CN112543763A (es)
AU (1) AU2019250359A1 (es)
BR (1) BR112020020652A2 (es)
CA (1) CA3096493A1 (es)
IL (1) IL277838A (es)
MX (1) MX2020010716A (es)
SG (1) SG11202010017SA (es)
WO (1) WO2019197466A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774837A1 (en) 2018-04-10 2021-02-17 Sanofi-Aventis Deutschland GmbH Method for cleavage of solid phase-bound peptides from the solid phase
CA3096495A1 (en) * 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Lixisenatide synthesis with capping
CN111116731A (zh) * 2020-01-09 2020-05-08 山东大学 一种基于可溶性疏水标记载体的液相法制备索马鲁肽的方法
CN116332810B (zh) * 2023-03-29 2023-11-07 上海嘉莱多生物技术有限责任公司 一种Fmoc-His(Trt)-Abe-OH的制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
US6956026B2 (en) 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
BR9811866A (pt) 1997-08-08 2000-08-15 Amylin Pharmaceuticals Inc Compostos agonistas de exendina
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
IL125314A (en) * 1998-07-12 2004-07-25 Peptor Ltd Processes for attaching amino acids using a bite - (trichloromethyl) carbonate
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
JP3854995B2 (ja) 2000-01-21 2006-12-06 関西ティー・エル・オー株式会社 細胞透過性キャリアペプチド
WO2001072412A1 (de) 2000-03-28 2001-10-04 Laser- Und Medizin-Technologie Gmbh Berlin Verfahren und vorrichtung zum aufbau und untersuchung von substanzbibliotheken
CA2490564A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US20050176079A1 (en) 2004-02-09 2005-08-11 Chu Yong L. Polypeptide bioconjugates, methods of making the bioconjugates and assays employing the bioconjugates
EP1756141B1 (en) 2004-06-14 2009-12-09 USV Ltd. Process for the preparation of peptides
US20080019911A1 (en) 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
WO2006134340A2 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
CN101217982B (zh) 2005-07-06 2012-10-10 生化学工业株式会社 药剂导入光交联透明质酸衍生物凝胶
CN101033249B (zh) * 2006-03-10 2011-05-11 周逸明 固相多肽合成比筏芦定的制备方法
CN101357938B (zh) * 2007-07-31 2013-07-03 周逸明 固相多肽合成Exenatide的制备方法
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
KR20110126589A (ko) * 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
RU2458066C1 (ru) 2011-05-31 2012-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Способ получения пептида эксенатида
BR112014002124A2 (pt) 2011-08-04 2017-02-21 Pharis Biotec Gmbh processo para preparar relaxina-2 humana
US20130289241A1 (en) * 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR20150039748A (ko) 2012-06-21 2015-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤의 유사체들
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014072916A1 (en) 2012-11-06 2014-05-15 Les Hopitaux Universitaires De Geneve Mimetic peptides
WO2014096150A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
CN103819553A (zh) 2013-12-27 2014-05-28 苏贤斌 一种使用固相和液相组合技术制备利西拉来的方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2016148213A1 (ja) 2015-03-17 2016-09-22 国立大学法人京都大学 血液脳関門透過性ペプチド
CN104844706B (zh) * 2015-06-10 2018-08-03 成都圣诺生物科技股份有限公司 一种合成利西拉来的方法
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
CN109641946A (zh) 2016-03-23 2019-04-16 巴切姆股份公司 胰高血糖素样肽的制备方法
WO2017189925A1 (en) * 2016-04-28 2017-11-02 C S Bio Co. Methods of preparing peptides
TW201821434A (zh) 2016-10-10 2018-06-16 法商賽諾菲公司 製備包含親脂性修飾的離胺酸側鏈的肽的方法
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
EP3774837A1 (en) 2018-04-10 2021-02-17 Sanofi-Aventis Deutschland GmbH Method for cleavage of solid phase-bound peptides from the solid phase

Also Published As

Publication number Publication date
JP7434169B2 (ja) 2024-02-20
EP3774837A1 (en) 2021-02-17
BR112020020652A2 (pt) 2021-03-02
WO2019197466A1 (en) 2019-10-17
KR20200142033A (ko) 2020-12-21
US11560402B2 (en) 2023-01-24
AU2019250359A1 (en) 2020-11-26
CN112543763A (zh) 2021-03-23
SG11202010017SA (en) 2020-11-27
IL277838A (en) 2020-11-30
JP2021521156A (ja) 2021-08-26
US20190330266A1 (en) 2019-10-31
CA3096493A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
NZ715038A (en) T cell receptors
PH12017502213A1 (en) Compositions and methods for treating celiac sprue disease
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EP4249097A3 (en) Fc binding proteins with cysteine in the c-terminal helical region
MX2018007581A (es) Dominios variables de inmunoglobulina mejorados.
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
SV2017005545A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
PH12017550134A1 (en) Il-37 variants
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение
GB2543713A (en) Polymeric proteins and uses thereof
NZ744289A (en) Composition containing amino acids
JOP20190259A1 (ar) بروتينات ربط مولد ضد مضادة لـ jagged1
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
MX2020010422A (es) Alfa-amilasa maltogenica variante.
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
MX2022003074A (es) Anticuerpos anti-cd371, y usos de los mismos.